Concepedia

Uday Kiran Veldandi

UK

Statistics

Publications

5

Citations

78

H-Index

5

Active since

2010

Affiliations

Novartis (Switzerland)(Current)

Novartis (India)

Uday Kiran Veldandi is an author at Novartis (Switzerland) specializing in medicine, oncology, and pharmacology.

Publications per year

2010–2023

5

Publications

5

Evaluation of tumor markers in southern Indian breast cancer patients.

Mahendar Porika, Nagulu Malotu, Uday Kiran Veldandi et al. · PubMed · 2010 · 21 citations

Medicine, Oncology, Pathology +15

Iptacopan in Idiopathic Immune Complex–Mediated Membranoproliferative Glomerulonephritis: Protocol of the APPARENT Multicenter, Randomized Phase 3 Study

Marina Vivarelli, Andrew S. Bomback, Matthias Meier et al. · Kidney International Reports · 2023 · 17 citations · Full text

Medicine, Immunology, Nephrology +17

Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group study

Kasra Shakeri‐Nejad, Vassilios Aslanis, Uday Kiran Veldandi et al. · International Journal of Clinical Pharmacology and Therapeutics · 2016 · 15 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects

Kasra Shakeri‐Nejad, Vassilios Aslanis, Uday Kiran Veldandi et al. · Clinical Therapeutics · 2015 · 14 citations

Medicine, Cardiology, Pharmacology +11

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipients with Hepatocellular Carcinoma

Gonzalo Sapisochín, Wei‐Chen Lee, Dong Jin Joo et al. · Annals of Transplantation · 2022 · 11 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

1–5 of 5